← Product Code [MRO](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/MRO) · K052663 # INO THERAPEUTICS INOBLENDER, MODEL 10004 (K052663) _Ino Therapeutics · MRO · Nov 4, 2005 · Anesthesiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/MRO/K052663 ## Device Facts - **Applicant:** Ino Therapeutics - **Product Code:** [MRO](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/MRO.md) - **Decision Date:** Nov 4, 2005 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 868.5165 - **Device Class:** Class 2 - **Review Panel:** Anesthesiology - **Attributes:** Therapeutic ## Indications for Use The INOblender provides user set concentrations of inhaled Nitric Oxide (NO), in a balance of nitrogen, mixed into a user settable constant flow of oxygen gas that is being delivered to a patient. The intended use for the INOblender is as a back up to a primary nitric oxide delivery system or for short term attended use when a primary delivery device cannot practicably be used. This intended use includes applications within a medical facility and transport outside of a medical facility. The INOblender is not intended for use as a primary NO delivery system for long-term use. ## Device Story INOblender is a pneumatic gas mixing apparatus; functions as a back-up system for inhaled Nitric Oxide (NO) delivery. Inputs: source gas (NO in nitrogen) and oxygen. Operation: manually mixes NO/nitrogen with oxygen to achieve user-set concentrations; delivers constant flow to patient. Used in medical facilities or during transport; operated by clinicians. Output: NO/oxygen gas mixture. Benefits: provides temporary, reliable NO delivery when primary systems fail or are impractical. Device is not for long-term primary therapy. ## Clinical Evidence Bench testing only. No clinical data provided. Testing included design verification, integrity, reliability, and performance testing against design input/output specifications and hazard/risk control requirements. ## Technological Characteristics Pneumatic gas mixing apparatus. Materials selected based on Fadassi FM-1 and Datex-Ohmeda INOvent. Complies with CGA 626 (Medical NO Gas Connections) and IEC 60601-1 (General requirements for medical electrical equipment). Standalone mechanical/pneumatic device. ## Regulatory Identification The nitric oxide administration apparatus is a device used to add nitric oxide to gases that are to be breathed by a patient. The nitric oxide administration apparatus is to be used in conjunction with a ventilator or other breathing gas administration system. ## Special Controls The special control for this device is FDA's “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.” The special control developed by the agency is a guidance document, entitled Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer. This guidance document identifies the risks associated with these types of devices and contains information that will help manufacturers address those risks. This document is available on FDA's website at http://www.fda.gov/cdrh/ode/1157.pdf. ## Predicate Devices - Fadassi Medical FM-1 NO Blender ([K003665](/device/K003665.md)) - Fadassi Medical FM-1 NO Blender ([K011874](/device/K011874.md)) ## Reference Devices - Datex-Ohmeda INOvent Delivery System ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K052663 Image /page/0/Picture/1 description: The image shows the logo for INC Therapeutics. The logo has the letters "INC" in large, bold, black font on the left side of the image. To the right of the letters is the word "Therapeutics" in a smaller, black font with a line underneath it. NOV - 4 2005 7601-B Murphy Drive Middleton, WI 53562 USA Tel. 608-831-4401 / Fax. 608-831-4409 | Subject: | 510(k) Summary of Safety and Effectiveness Information for the | | |-------------------|----------------------------------------------------------------|--| | | INO Therapeutics INOblender | | | Proprietary Name: | INOblender | | | Common Name: | Nitric Oxide Administration Apparatus - Back-up System | | | Classification: | Class II, 21CFR868.5165, MRO | | | Panel: | Anesthesiology | | | Contact Person: | Frederick Montgomery, Vice President, Medical Devices | | The 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 1992. The INOblender is substantially equivalent to the Fadassi Medical FM-1 NO Blender, which was cleared by FDA with 510(k) premarket notification numbers K003665 and K011874. Indications for use: The INOblender provides user set concentrations of inhaled Nitric Oxide (NO), in a balance of nitrogen, mixed into a user settable constant flow of oxygen gas that is being delivered to a patient. The intended use for the INOblender is as a back up to a primary nitric oxide delivery system or for short term attended use when a primary delivery device cannot practicably be used. This intended use includes applications within a medical facility and transport outside of a medical facility. The INOblender is not intended for use as a primary NO delivery system for long-term use. The INOblender was designed to comply with the limited applicable portions of the following: - 1. CGA 626: Medical NO Gas Connections. - 2. IEC 60601-1: Medical Electrical Equipment (for general requirements). - 3. FDA Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer. The materials selected were based upon the Fadasis FM-1 NO Blender and the Datex-Ohmcda INOvent Delivery System. All testing indicated the INOblender met its design input specifications, design output specifications, hazard analysis and risk control requirements. Testing completed included: - 1. INOblender Test Plan - 2. INOblender Integrity Test Report - 3. INOblender Reliability Testing - 4. INOblender Verification Test Report - 5. INOblender Testing Against Predicate Test Plan {1}------------------------------------------------ Image /page/1/Picture/0 description: The image shows the logo for INC Therapeutics. The logo is in black and white and features the letters "INC" in a bold, sans-serif font. The word "Therapeutics" is written in a smaller, serif font to the right of the "C" in "INC". A horizontal line is underneath the word "Therapeutics". 7601-B Murphy Drive Middleton, WI 53562 USA Tel. 608-831-4401 / Fax. 608-831-4409 ## INO Therapeutics INOblender Device Name - Proprietary: INOblender Device Name -- Common: Nitric Oxide Mixer Device Name - Classification: Nitric Oxide Administration Apparatus, Back-up System Device Panel: Anesthesiology Device Classification: Class II - 21CFR868.5165, 73 MRO Predicate Devices: Fadasis Medical, Inc. FM-1 NO Blender 510(k) Numbers K001874, K003665 Performance Standards: To the best of INO Therapeutics' knowledge, performance standards have not been promulgated by FDA for this device. Establishment Registration Number: 9062609 Owner/Operator Number: 3004531588 Facility Information: INO Therapeutics LLC 7601-B Murphy Drive Middleton, WI 53562 Telephone: (608) 831-4401 Fax: (608) 831-4409 Webpage: www.inotherapeutics.com {2}------------------------------------------------ Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of an eagle. Public Health Service NOV - 4 2005 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Frederick Montgomery Vice President, Medical Devices INO Therapeutics 7601-B Murphy Drive Middletown, Wisconsin 53562 Re: K052663 Trade/Device Name: INO Therapeutics INOblender Regulation Number: 21 CFR 868.5165 Regulation Name: Nitric Oxide Administration Apparatus Regulatory Class: II Product Code: MRO Dated: October 25, 2005 Received: October 26, 2005 Dear Mr. Montgomery: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Mr. Montgomery Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Chiu-Ling, Ph.D. Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number (if known): Device Name: INO Therapeutics INOblender Indications For Use: The INOblender provides user set concentrations of inhaled Nitric Oxide (NO), in a balance of nitrogen, mixed into a user settable constant flow of oxygen gas that is being delivered to a patient. The intended use for the INOblender is as a back up to a primary nitric oxide delivery system or for short term attended use when a primary delivery device cannot practicably be used. This intended use includes applications within a medical facility and transport outside of a medical facility. The INOblender is not intended for use as a primary NO delivery system for long-term use. Prescription Use (Part 21 CFR 801 Subpart D) and/or Over-the-Counter-Use (Part 21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Aung Suleons Page 1 of 1 vision of Anesthesiology, General Hospital, intection Control, Dental Devices 50(k) Number: K052 61 --- **Source:** [https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/MRO/K052663](https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/MRO/K052663) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com